BioCentury
ARTICLE | Clinical News

Lenvima lenvatinib mesylate regulatory update

May 23, 2016 7:00 AM UTC

FDA approved an sNDA from Eisai for Lenvima lenvatinib to treat advanced renal cell carcinoma (RCC) in combination with Afinitor everolimus following 1 prior anti-angiogenic therapy. Lenvima is approved in the U.S. to treat locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ...